Overview
- The CNIO team reported in PNAS that simultaneously targeting KRAS, EGFR and STAT3 eliminated pancreatic ductal adenocarcinoma in multiple mouse models.
- In patient‑derived xenograft studies, 16 of 18 mice remained disease‑free roughly 200 days after treatment, with no significant toxicity observed.
- The regimen used daraxonrasib for KRAS, afatinib for EGFR and the experimental STAT3 degrader SD36, preventing adaptive resistance seen with single‑agent KRAS inhibitors.
- Researchers cautioned the results are preclinical and estimated a phase‑1 trial would likely not begin for about three years without acceleration.
- Funding from Fundación CRIS and the European Research Council supported the work, and the team formed Vega Oncotargets to advance drug optimization and navigate regulatory pathways.